A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids
: Senkowski Wojciech., Gall-Mas Laura, Falco Matias Marin, Li Yilin, Lavikka Kari, Kriegbaum Mette C., Oikkonen Jaana, Bulanova Daria, Pietras Elin J., Voßgröne Karolin, Chen Yan Jun., Erkan Erdogan Pekcan, Dai Jun, Lundgren Anastasia, Grønning Høg Mia Kristine, Larsen Ida Marie, Lamminen Tarja, Kaipio Katja, Huvila Jutta, Virtanen Anni, Engelholm Lars, Christiansen Pernille, Santoni-Rugiu Eric, Huhtinen Kaisa, Carpén Olli, Hynninen Johanna, Hautaniemi Sampsa, Vähärautio Anna, Wennerberg Krister
Publisher: Cell Press
: 2023
: Developmental Cell
: Developmental Cell
: 58
: 12
: 1106
DOI: https://doi.org/10.1016/j.devcel.2023.04.012
: https://doi.org/10.1016/j.devcel.2023.04.012
: https://research.utu.fi/converis/portal/detail/Publication/180234529
The broad research use of organoids from high-grade serous ovarian cancer (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here, we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (53% vs. 23%–38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic, and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in a culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data are explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.
